Benefits of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction
Sacubitril/valsartan (combined as an ARNI - angiotensin receptor-neprilysin inhibitor) significantly reduces cardiovascular death and heart failure hospitalizations in patients with HFrEF, and should replace ACE inhibitors or ARBs in symptomatic patients already on guideline-directed medical therapy. 1, 2, 1
Primary Mortality and Morbidity Benefits
The landmark evidence demonstrates that sacubitril/valsartan provides:
- 20% reduction in cardiovascular death or HF hospitalization compared to enalapril 2, 3
- 16% reduction in all-cause mortality (HR 0.84,95% CI 0.76-0.93) 3
- 20% reduction in cardiovascular mortality specifically 2
- Reduced HF hospitalizations with number needed to treat of 11 to prevent one hospitalization 4
- Fewer emergency department visits (NNT = 69) 4
These benefits were consistent across subgroups regardless of baseline blood pressure or hypertension status 3.
Cardiac Function and Remodeling Improvements
Beyond mortality reduction, sacubitril/valsartan produces measurable improvements in cardiac structure and function:
- Increased left ventricular ejection fraction (LVEF): Studies show LVEF improvement from median 35.5% to 40.6% at 6 months 5, with sustained benefits up to 2 years 6
- Reverse cardiac remodeling: Significant reductions in left ventricular end-diastolic diameter, end-systolic diameter, and left atrial diameter 7, 6
- Improved hemodynamic profiles: 53% of patients showed hemodynamic improvement (normalized filling pressures and cardiac output), which independently predicted better outcomes 8
- Reduced NT-proBNP levels: Progressive and sustained reductions in natriuretic peptide levels correlating with clinical improvement 7, 6
Functional Status and Quality of Life
Sacubitril/valsartan improves patient-centered outcomes including:
- Enhanced 6-minute walk distance 7
- Improved NYHA functional class 3, 7
- Better Kansas City Cardiomyopathy Questionnaire scores 7
- Reduced progression of heart failure among survivors 3
Clinical Implementation Algorithm
When to use sacubitril/valsartan:
Primary indication: Symptomatic HFrEF patients (LVEF ≤40%) in NYHA class II-III who remain symptomatic despite treatment with ACE inhibitor/ARB, beta-blocker, and mineralocorticoid receptor antagonist 1, 9
Replacement strategy: Switch from ACE inhibitor or ARB to sacubitril/valsartan (Class I, Level B recommendation) 1, 2, 1
De novo initiation: Can be started as first-line therapy in newly diagnosed HFrEF or in hospitalized patients before discharge, simplifying management rather than requiring ACE inhibitor uptitration first 9
Dosing approach:
Critical Safety Considerations
Mandatory washout period: Allow 36 hours between last ACE inhibitor dose and first sacubitril/valsartan dose to prevent angioedema 2, 9, 10
Absolute contraindications 10:
- History of angioedema with ACE inhibitor or ARB
- Concomitant ACE inhibitor use
- Pregnancy (causes fetal toxicity)
- Concomitant aliskiren in diabetic patients
Monitor for:
- Symptomatic hypotension (occurs more frequently than with enalapril, but manageable) 2, 3
- Renal function changes
- Hyperkalemia
- Angioedema (rare, <1%, but serious) 2
Special Populations
End-stage renal disease: Recent evidence suggests sacubitril/valsartan reduces 5-year mortality (39.3% vs 54.7%) and improves LVEF even in HFrEF patients with coexisting ESRD on dialysis 11, 12, though this was not studied in the original trials.
Without beta-blocker: Sacubitril/valsartan may be even more effective in patients not on beta-blockers (HR 0.61 for primary endpoint vs 0.82 in those on beta-blockers), but benefits occur regardless of beta-blocker use 13.
Guideline Recommendations Hierarchy
The 2022 ACC/AHA/HFSA guidelines now position sacubitril/valsartan as part of the foundational "quadruple therapy" for HFrEF alongside beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors 14. This represents a Class I, Level B-R recommendation for replacing ACE inhibitors in symptomatic patients 2, 9.
The European Society of Cardiology similarly gives sacubitril/valsartan a Class I, Level B recommendation as replacement therapy for ACE inhibitors in ambulatory HFrEF patients who remain symptomatic despite optimal medical therapy 1.